98546-30-6

Upstream product

• 67-56-1 methanol 
• 3558-19-8 methyl 2-amino-4-nitrobenzoate 
• 299173-24-3 [3-iodo-4-(methoxycarbonyl)]benzoic acid 
• 6326-42-7 2-iodo-4-nitrobenzoic acid methyl ester 
• 619-45-4 4-methoxycarbonyl aniline 
• 89459-38-1 4-nitro-2-iodobenzoic acid 

Downstream Products

• 488082-61-7 2-(2-acetylamino-5-iodo-phenylethynyl)-4-iodo-benzoic acid methyl ester 
• 488082-60-6 C₂₆H₃₃N₇O₃ 
• 488082-62-8 2-(2-acetylamino-5-trimethylsilanylethynyl-phenylethynyl)-4-trimethylsilanylethynyl-benzoic acid methyl ester 

Relevant academic research and scientific papers

ANTI-EGFR ANTIBODY DRUG CONJUGATES

The invention relates to anti-Epidermal Growth Factor Receptor (EGFR) antibody drug conjugates (ADCs) which inhibit Bcl-xL, including compositions and methods of using said ADCs.

ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES

The invention relates to anti-CD98 antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.

ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES

The invention relates to B7 homology 3 protein (B7-H3) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.

BROAD SPECTRUM ANTIVIRAL COMPOUNDS AND USES THEREOF

Disclosed herein, inter alia, are agents having antiviral activity and methods of use thereof.

ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES

The invention relates to anti-CD98 antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.

BCL XL INHIBITORY COMPOUNDS HAVING LOW CELL PERMEABILITY AND ANTIBODY DRUG CONJUGATES INCLUDING THE SAME

The present disclosure concerns Bcl-xL inhibitors having low cell permeability, antibody drug conjugates (ADCs) comprising the inhibitors, synthons useful for synthesizing the ADCs, compositions comprising the inhibitors or ADCs, and various methods of using the inhibitors and ADCs.

Hydrogen Bond-Stabilized Helix Formation of a m-Phenylene Ethynylene Oligomer

(Matrix Presented) Incorporation of a single hydrogen bonded β-turn mimic in the backbone of a m-phenylene ethynylene oligomer is shown to affect the thermodynamic properties of the folding reaction. Oligomers 1 and 2 both undergo solvophobic helix formation, but hydrogen bonded oligomer 1 was found to form a more stable helix with a higher tolerance to solvent denaturation than isomeric, non-hydrogen bonded oligomer 2.